Results and adverse events of personalized peptide receptor radionuclide therapy with (90)Yttrium and (177)Lutetium in 1048 patients with neuroendocrine neoplasms

INTRODUCTION: Peptide receptor radionuclide therapy (PRRT) of patients with somatostatin receptor expressing neuroendocrine neoplasms has shown promising results in clinical trials and a recently published phase III study. METHODS: In our center, 2294 patients were screened between 2004 and 2014 by...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Udgivet i:	Oncotarget
Main Authors:	Baum, Richard P., Kulkarni, Harshad R., Singh, Aviral, Kaemmerer, Daniel, Mueller, Dirk, Prasad, Vikas, Hommann, Merten, Robiller, Franz C., Niepsch, Karin, Franz, Holger, Jochems, Arthur, Lambin, Philippe, Hörsch, Dieter
Format:	Artigo
Sprog:	Inglês
Udgivet:	Impact Journals LLC 2018
Fag:	Research Paper
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5908296/ https://ncbi.nlm.nih.gov/pubmed/29682195 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24524
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Results and adverse events of personalized peptide receptor radionuclide therapy with (90)Yttrium and (177)Lutetium in 1048 patients with neuroendocrine neoplasms

Lignende værker